A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Active:	No
Cancer Type:	Hodgkin Lymphoma	NCT ID:	NCT01716806
Trial Phases:	Phase II	Protocol IDs:	SGN35-015 (primary)
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Seagen Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT01716806

Summary

This trial will study brentuximab vedotin to find out whether it is an effective
treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants
in this study will be older or will have other conditions that make them unable to have
standard chemotherapy treatment. The study will look at brentuximab vedotin alone and
combined with other drugs.

Objectives

This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin
as monotherapy and in combination with other agents as frontline therapy. There are 6
parts of the study. The population to be studied includes treatment-naïve patients with
classical Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing
peripheral T-cell lymphoma (PTCL).

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.